Literature DB >> 19294496

Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Eliseu Felippe dos Santos1, Estela Natacha Brandt Busanello, Anelise Miglioranza, Angela Zanatta, Alethea Gatto Barchak, Carmen Regla Vargas, Jonas Saute, Charles Rosa, Maria Júlia Carrion, Daiane Camargo, André Dalbem, Jaderson Costa da Costa, Sandro René Pinto de Sousa Miguel, Carlos Roberto de Mello Rieder, Moacir Wajner.   

Abstract

In the present work we measured blood levels of total homocysteine ((t)Hcy), vitamin B(12) and folic acid in patients with Parkinson s disease (PD) and in age-matched controls and searched for possible associations between these levels with smoking, alcohol consumption, L-DOPA treatment and disease duration in PD patients. We initially observed that plasma (t)Hcy levels were increased by around 30 % in patients affected by PD compared to controls. Linear correlation, multiple regression and comparative analyses revealed that the major determinant of the increased plasma concentrations of (t)Hcy in PD patients was folic acid deficiency, whereas in controls (t)Hcy levels were mainly determined by plasma vitamin B(12) concentrations. We also observed that alcohol consumption, gender and L-DOPA treatment did not significantly alter plasma (t)Hcy, folic acid and vitamin B(12) levels in parkinsonians. Furthermore, disease duration was positively associated with (t)Hcy levels and smoking was linked with a deficit of folic acid in PD patients. Considering the potential synergistic deleterious effects of Hcy increase and folate deficiency on the central nervous system, we postulate that folic acid should be supplemented to patients affected by PD in order to normalize blood Hcy and folate levels, therefore potentially avoiding these risk factors for neurologic deterioration in this disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294496     DOI: 10.1007/s11011-009-9139-4

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  66 in total

1.  Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.

Authors:  T Müller; B Werne; B Fowler; W Kuhn
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

2.  Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.

Authors:  F Blandini; R Fancellu; E Martignoni; A Mangiagalli; C Pacchetti; A Samuele; G Nappi
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

3.  Benefit of folic acid supplementation in parkinsonian patients treated with levodopa.

Authors:  T Müller; D Woitalla; W Kuhn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

4.  Pathogenesis of subacute combined degeneration: a result of methyl group deficiency.

Authors:  J M Scott; J J Dinn; P Wilson; D G Weir
Journal:  Lancet       Date:  1981-08-15       Impact factor: 79.321

5.  Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.

Authors:  Zoran Todorović; Eleonora Dzoljić; Ivana Novaković; Dusko Mirković; Radan Stojanović; Zorica Nesić; Maja Krajinović; Milica Prostran; Vladimir Kostić
Journal:  J Neurol Sci       Date:  2006-06-13       Impact factor: 3.181

Review 6.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

7.  Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage.

Authors:  B C Blount; M M Mack; C M Wehr; J T MacGregor; R A Hiatt; G Wang; S N Wickramasinghe; R B Everson; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 8.  The many facets of hyperhomocysteinemia: studies from the Framingham cohorts.

Authors:  Jacob Selhub
Journal:  J Nutr       Date:  2006-06       Impact factor: 4.798

Review 9.  Oxidative mechanisms in nigral cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  Mov Disord       Date:  1998       Impact factor: 10.338

Review 10.  Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate.

Authors:  J W Langston
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

View more
  18 in total

1.  Association between hyperhomocysteinemia and stroke with atherosclerosis and small artery occlusion depends on homocysteine metabolism-related vitamin levels in Chinese patients with normal renal function.

Authors:  Guan-Hui Wu; Fan-Zhen Kong; Xiao-Feng Dong; De-Feng Wu; Qian-Zhu Guo; Ai-Rong Shen; Qing-Zhang Cheng; Wei-Feng Luo
Journal:  Metab Brain Dis       Date:  2017-03-06       Impact factor: 3.584

2.  Serum iron, vitamin B12 and folic acid levels in Parkinson's disease.

Authors:  Gulizar Madenci; Sule Bilen; Berna Arli; Mustafa Saka; Fikri Ak
Journal:  Neurochem Res       Date:  2012-02-26       Impact factor: 3.996

3.  Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson's Disease.

Authors:  Saurabh Srivastav; Sandeep Kumar Singh; Amarish Kumar Yadav; Saripella Srikrishna
Journal:  Neurochem Res       Date:  2015-05-12       Impact factor: 3.996

4.  Paraquat Exposure Increases Oxidative Stress Within the Dorsal Striatum of Male Mice With a Genetic Deficiency in One-carbon Metabolism.

Authors:  Nafisa M Jadavji; Lauren K Murray; Joshua T Emmerson; Chris A Rudyk; Shawn Hayley; Patrice D Smith
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

Review 5.  An umbrella review of systematic reviews with meta-analysis on the role of vitamins in Parkinson's disease.

Authors:  Sama Rahnemayan; Sasan Ghazanfar Ahari; Reza Rikhtegar; Sevda Riyahifar; Sarvin Sanaie
Journal:  Acta Neurol Belg       Date:  2022-08-03       Impact factor: 2.471

Review 6.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

Review 7.  Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Authors:  Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-07-14       Impact factor: 3.575

8.  Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and L-Dopa Treatment.

Authors:  Agata Rozycka; Pawel P Jagodzinski; Wojciech Kozubski; Margarita Lianeri; Jolanta Dorszewska
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

9.  Parkinson's Disease and Homocysteine: A Community-Based Study in a Folate and Vitamin B12 Deficient Population.

Authors:  Zhang Wei; Wang Tiandong; Li Yang; Meng Huaxing; Min Guowen; Fang Yalan; Niu Xiaoyuan
Journal:  Parkinsons Dis       Date:  2016-08-31

Review 10.  Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson's Disease.

Authors:  Paula Perez-Pardo; Mitch Hartog; Johan Garssen; Aletta D Kraneveld
Journal:  Curr Behav Neurosci Rep       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.